World's Best Scientists 2026 revealed!
David P. Steensma

David P. Steensma

D-Index & Metrics

Medicine

D-Index
86
Citations
28928
World Ranking
14071
National Ranking
7140

David P. Steensma publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where David P. Steensma sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 780 publications — 86th percentile

86% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

David P. Steensma D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where David P. Steensma sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 86 D-Index — 31st percentile

31% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

David P. Steensma is affiliated with Harvard University in the United States. Their research primarily focuses on medicine, with a significant body of work in hematology, genetics, public health, environmental and occupational health, oncology, and molecular biology. This broad scope supports investigation into multiple interconnected areas within medical science.

The main topics covered in their publications include:

  • Acute Myeloid Leukemia Research
  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Acute Lymphoblastic Leukemia Research
  • Hematopoietic Stem Cell Transplantation
  • Chronic Myeloid Leukemia Treatments
  • Multiple Myeloma Research and Treatments
  • Cancer Genomics and Diagnostics

Steensma has contributed to various academic venues, with frequent publications appearing in:

  • Mayo Clinic Proceedings
  • Blood
  • Leukemia
  • Blood Advances
  • Journal of Clinical Oncology

Coauthorship is an integral part of their scholarly output. Some of the most frequent collaborators include:

  • Mikkael A. Sekeres
  • Rami S. Komrokji
  • Gail J. Roboz
  • Amy E. DeZern
  • Robert A. Kyle

Among the recent significant publications are:

  • Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms, 2021, Leukemia
  • Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes, 2021, Journal of Clinical Oncology
  • Bone marrow niches in haematological malignancies, 2020, Nature reviews. Cancer
  • SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS, 2020, Blood
  • Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study, 2020, Blood

Best Publications

  • Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes

    David P. Steensma;Rafael Bejar;Siddhartha Jaiswal;R. Coleman Lindsley

  • MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients

    Animesh D. Pardanani;Ross L. Levine;Terra Lasho;Yana Pikman

  • Acute myeloid leukemia ontogeny is defined by distinct somatic mutations

    R. Coleman Lindsley;Brenton G. Mar;Emanuele Mazzola;Peter V. Grauman

  • Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials.

    Julia Bohlius;Kurt Schmidlin;Corinne Brillant;Guido Schwarzer

  • The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes.

    David P. Steensma;David P. Steensma;Gordon W. Dewald;Gordon W. Dewald;Terra L. Lasho;Terra L. Lasho;Heather L. Powell;Heather L. Powell

  • TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients.

    Rafael Bejar;Allegra Lord;Kristen Stevenson;Michal Bar-Natan

  • Validation of a Prognostic Model and the Impact of Mutations in Patients With Lower-Risk Myelodysplastic Syndromes

    Rafael Bejar;Kristen E. Stevenson;Bennett A. Caughey;Omar Abdel-Wahab

  • Somatic Mutations Predict Poor Outcome in Patients With Myelodysplastic Syndrome After Hematopoietic Stem-Cell Transplantation

    Rafael Bejar;Kristen E. Stevenson;Bennett Caughey;R. Coleman Lindsley

  • Multicenter Study of Decitabine Administered Daily for 5 Days Every 4 Weeks to Adults With Myelodysplastic Syndromes: The Alternative Dosing for Outpatient Treatment (ADOPT) Trial

    David P. Steensma;Maria R. Baer;James L. Slack;Rena Buckstein

  • A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia

    Ruben A. Mesa;David P. Steensma;David P. Steensma;Animesh Pardanani;Animesh Pardanani;Chin Yang Li;Chin Yang Li

  • Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms.

    Ofir Wolach;Ofir Wolach;Ofir Wolach;Rob S. Sellar;Rob S. Sellar;Rob S. Sellar;Kimberly Martinod;Deya Cherpokova

  • Bone marrow niches in haematological malignancies.

    Simón Méndez-Ferrer;Simón Méndez-Ferrer;Simón Méndez-Ferrer;Dominique Bonnet;David P. Steensma;Robert P. Hasserjian

  • Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes.

    David A Sallman;Amy E DeZern;Guillermo Garcia-Manero;David P Steensma

  • The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice

    Elizabeth C. Townsend;Mark A. Murakami;Alexandra Christodoulou;Amanda L. Christie

  • The JAK2V617F tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates

    Ayalew Tefferi;Terra L. Lasho;Susan M. Schwager;David P. Steensma

  • The Myelofibrosis Symptom Assessment Form (MFSAF): An evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis

    Ruben A. Mesa;Susan Schwager;Deepti Radia;Andrea Cheville

  • SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value

    Mrinal M. Patnaik;Terra L. Lasho;Janice M. Hodnefield;Ryan A. Knudson

  • The Myelodysplastic Syndromes: Diagnosis and Treatment

    David P. Steensma;John M. Bennett

  • TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups

    Detlef Haase;Kristen E Stevenson;Donna Neuberg;Jaroslaw P Maciejewski

  • SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS

    Luca Malcovati;Kristen Stevenson;Elli Papaemmanuil;Donna Neuberg

Frequent Co-Authors

Mikkael A. Sekeres
Mikkael A. Sekeres Cleveland Clinic
Richard Stone
Richard Stone Harvard University
Guillermo Garcia-Manero
Guillermo Garcia-Manero The University of Texas MD Anderson Cancer Center
Daniel J. DeAngelo
Daniel J. DeAngelo Harvard University
Robert A. Kyle
Robert A. Kyle Mayo Clinic
Ayalew Tefferi
Ayalew Tefferi Mayo Clinic
Alan F. List
Alan F. List Precision BioSciences
Hagop M. Kantarjian
Hagop M. Kantarjian The University of Texas MD Anderson Cancer Center
Donna Neuberg
Donna Neuberg Harvard University
Benjamin L. Ebert
Benjamin L. Ebert Harvard University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring related online degrees can greatly expand your career pathways in the healthcare and medical fields. For those interested in healthcare administration, pursuing top online mha programs that are cahme accredited provides a flexible, reputable option to develop leadership skills for management roles.

Registered nurses looking to advance their education may benefit from rn to bsn no clinical hours programs. These online options are ideal for working nurses who need a non-traditional pathway that doesn't require in-person clinical components.

For those seeking to further specialize, doctoral programs in nursing are becoming more accessible. The quickest dnp program options allow experienced nurses to achieve a terminal degree in less time, while the cheapest online dnp programs help reduce the financial barriers often associated with advanced education.

Whether you’re looking to move into healthcare management, advance your clinical nursing career, or pursue doctoral studies, a growing number of online degrees can make your goals more achievable than ever.

Best Scientists Citing David P. Steensma

Trending Scientists

Recently Published Articles